Filter By:
January 15, 2021Firm News
Gunderson Dettmer Announces New Partners

Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP has elected six new partners, effective January 1. The elevations span the U.S. and add to the firm’s corporate and securities, venture and growth equity fund, public offerings/public companies, executive compensation and tax practices.

More
January 14, 2021Client News
HyTrust Acquisition by Entrust

Gunderson Dettmer represented client HyTrust, an innovative provider of virtualized and multi-cloud data encryption, in its acquisition by Entrust.

More
January 12, 2021Client Alerts
2020 Year-End Executive Compensation Matters: Annual Equity Compensation Award Reporting Reminders

Employers must file information returns with the Internal Revenue Service and provide employees with information statements related to incentive stock option exercises that occurred during calendar year 2020. Similarly, employers (typically relevant only for public companies) must file information returns with the IRS and provide employees with information statements related to initial transfers of stock acquired during 2020 under an employee stock purchase plan that complies with Internal Revenue Code Section 423.

More
January 12, 2021Client News
Gro Intelligence Raises $85M Series B Financing

Gunderson Dettmer represented client Gro Intelligence, an AI-powered insights company, in its $85 million Series B financing round co-led by Intel Africa and Africa Internet Ventures.

More
January 11, 2021Client News
Genalyte Raises $50M in Financing

Gunderson Dettmer represented client Genalyte, a leading diagnostics and analytics company, in its $50 million financing round led by Verily.

More
January 11, 2021Client Alerts
PPP Update: January 2021

On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law.

More
January 8, 2021Client News
Affinivax $226M Series C Financing

Gunderson Dettmer represented client Affinivax, a clinical stage biopharmaceutical company, in its $226 million Series C financing co-led by Rock Springs Capital and Foresite Capital.

More
January 7, 2021Client News
Xencor Collaboration with MD Anderson

Gunderson Dettmer represented client Xencor, a clinical-stage biopharmaceutical company, in its collaboration agreement with MD Anderson to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.

More
January 6, 2021Client News
Dragoneer Investment in PointClickCare

Gunderson Dettmer represented Dragoneer in increasing its investment in PointClickCare, a cloud-based healthcare software for the long-term and post-acute care market.

More
December 22, 2020Client News
WeRide Raises $200M Series B Financing

Gunderson Dettmer represented client WeRide, a Chinese startup developing autonomous vehicles, in its $200 million Series B financing round led by Yutong Group.

More
December 15, 2020Client News
Overland Pharma Joint Venture with Allogene Therapeutics

Gunderson Dettmer represented client Overland Pharma in its joint venture with Allogene Therapeutics forming new company, Allogene Overland Biopharm, a separate venture that will develop, manufacture and commercialize allogeneic CAR T (AlloCAR T™) therapies for patients with cancer in greater China, Taiwan, South Korea and Singapore.

More
December 15, 2020Firm News
Singapore Office Ranked by Chambers

Gunderson Dettmer’s Singapore office, opened in 2016 to meet the needs of emerging companies and venture capital investors across SE Asia, was ranked in Band 1 by Chambers and Partners in its 2021 Asia-Pacific guide for its Startups & Emerging Companies practice. Singapore managing partner Jonathan Pentzien was also recognized by Chambers in Band 1 as a leading individual for Startups & Emerging Companies. Chambers and Partners is the leading independent legal ranking publication globally and ranks Gunderson highly across all of its practice area

More
December 14, 2020Client News
Dubsmash Acquisition by Reddit

Gunderson Dettmer represented client Dubsmash, a lip-syncing video application, in its acquisition by Reddit.

More
December 14, 2020Client News
Overland Pharma Joint Venture with ADC Therapeutics

Gunderson Dettmer represented client Overland Pharma in its joint venture with ADC Therapeutics forming new company, Overland ADCT BioPharma (CY) Limited, that will develop and commercialize four of ADC Therapeutics’ antibody drug conjugate (ADC) product candidates for difficult-to-treat hematologic and solid tumors in greater China and Singapore.

More
December 10, 2020Client News
Cityblock Health Raises $160M Series C Financing

Gunderson Dettmer represented client Cityblock Health, a startup improving health care for low-income patients with complex medical needs, in its $160 million Series C financing led by General Catalyst.

More
December 9, 2020Client Alerts
New California Law Requires Diversity on Corporate Boards of Directors

With the passage of Senate Bill 826 at the end of September 2018, California became the first state in the U.S. to require public companies incorporated in California or other public companies with their principal executive offices in California (according their Annual Report on Form 10-K) to have specified numbers of women serving on their Boards of Directors. In addition, with the passage of Assembly Bill 979, these same public companies will be required to have at least two members of their Boards of Directors from an “underrepresented community.”

More
December 9, 2020Client News
PepGen Raises $45M Series A Financing

Gunderson Dettmer represented client PepGen, a therapeutics company targeting severe neuromuscular diseases, in its $45 million Series A financing led by RA Capital Management.

More